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Achilles tendon pathology (ATP) is a degenerative condition with known genetic risk 
factors1. Excessive tenocyte apoptosis has been observed in tendinopathy and 
components of the apoptosis pathway have previously been implicated in the 
aetiology of ATP2. Caspases are a large family of cysteine proteases that play a key 
role in the execution and regulation of apoptosis3. Caspase-3 is one of three known 
effector caspases, which can selectively cleave target proteins, such as Bcl-2, after 
aspartate residues in their primary sequence3. 
 
The rs1049253 single nucleotide polymorphism (SNP) lies within a microRNA 
(miRNA) binding site in the 3’ untranslated region (UTR) of CASP34 (Figure 1). This 
SNP is associated with the risk of certain cancers and the CC genotype is associated 
with lower levels of CASP3 mRNA4. MiRNAs can bind mRNAs and have an important 
role in regulating apoptosis associated with carcinogenesis4. Our aim was to 
determine whether CASP3 rs1049253 was associated with ATP in a British cohort. 
1. Introduction 
We recruited 261 (130 ATP cases and 131 asymptomatic controls) British Caucasian 
participants for this genetic association study. ATP cases were clinically diagnosed 
with insertional tendinopathy (INS), noninsertional tendinopathy (NON), Achilles 
tendon rupture or mixed pathology. Written informed consent was obtained and all 
participants completed a physical activity/medical history/injury questionnaire. The 
study was approved by the Research Ethics Committee of the University of 
Northampton, UK. DNA was extracted from 2 mL of saliva collected using ORAGENE-
DNA collection kits (OG-500) and DNA purification was carried out using the prepIT-
L2P DNA extraction kit (DNA Genotek Inc., Ontario, Canada). 
 
TaqMan assay technology was used to genotype all participants using real-time PCR, 
with 10 ng of DNA and positive and negative controls included in each PCR run. The 
TaqMan Genotyping Assay contained FAM and VIC reporter dye labelled probes, with 
ROX dye as the passive reference. Genotypes were automatically called using 
StepOne Software, version 2.1 (Applied Biosystems, Foster City, California, USA) 
(Figure 2). 
 
Data were analysed using IBM SPSS Statistics, version 20 (IBM Corp. Armonk, NY). 
A Pearson’s chi-squared (X2) or Fisher’s exact test was used to analyse differences in 
genotype and allele frequencies for the rs1049253 variant. We compared the 
collective ATP group against controls. We also conducted sub-analyses for the 
different types of tendinopathy. Rupture and mixed pathology cases were excluded 
from sub-analyses. Hardy-Weinberg equilibrium (HWE) was established and p < 0.05 
was considered to be a deviation from HWE. 
2. Methods 
3. Results 
CASP3 CON    ATP INS  NON 
rs1049253 n=131 n=130 n=29 n=47 
TT 62.6 (82) 61.5 (80) 72.4 (21) 55.3 (26) 
CT 34.4 (45) 33.1 (43) 20.7 (6) 38.3 (18) 
CC 3.1 (4) 5.4 (7) 6.9 (2) 6.4 (3) 
p-value   0.643 0.218 0.456 
MAF 20.2 (53)   21.9 (57) 17.2 (10) 25.5 (24) 
p-value 0.635 0.605 0.284 
HWE 0.461   0.700 0.139  0.961  
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4. Discussion 
Table 1a. Genotype and allele frequency distribution of CASP3 rs1049253 within 
cases (ATP/INS/NON) and controls (CON).  
We found no significant difference in genotype (p = 0.643) or allele (p = 0.635) 
frequencies between the ATP group and controls (Table 1a). However, we did find a 
genotypic association (p = 0.036) between male insertional tendinopathy cases 
(INS) and male controls (CON) (Table 1b). Specifically, the CC genotype appeared 
to increase the risk of insertional tendinopathy in males (p = 0.045, OR = 12.46, 
95% CI 1.05-147.46). Furthermore, CASP3 rs1049253 was not in HWE in the male 
INS group (p =  0.024). There were no significant differences between male 
ATP/NON and CON, nor with female ATP/INS/NON and female CON (data not 
shown). It it important that these data are viewed with caution due to the relatively 
small sample size, which might also explain the deviation from HWE observed in the 
male INS group. Therefore replication in a larger cohort would be necessary to 
increase confidence. 
 
Our preliminary data infer a possible role for the rs1049253 variant as a risk factor 
for insertional tendinopathy in British males. Although additional research is needed, 
these results could further implicate the involvement of the apoptosis pathway in the 
development of ATP and could justify the inclusion of this variant in a risk 
assessment model for ATP. Such models alone will not predict or diagnose ATP, due 
to the multifactorial nature of this condition. Nevertheless, in combination with the 
alteration of modifiable risk factors such as training, could hold potential in lowering 
the risk of injury5. 
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Figure 2. Typical allelic discrimination plot for CASP3 rs1049253. 
CASP3 Male CON Male ATP Male INS Male NON 
rs1049253 n=82 n=80 n=15 n=27 
TT 68.3 (56) 58.8 (47) 73.3 (11) 55.6 (15) 
CT 30.5 (25) 32.5 (26) 13.3 (2) 33.3 (9) 
CC 1.2 (1) 8.8 (7) 13.3 (2) 11.1 (3) 
p-value   0.072 0.036 0.064 
MAF 16.5 (27)   25.0 (40) 20.0 (6) 27.8 (15) 
p-value 0.058 0.976 0.219 
HWE 0.326   0.233 0.024 0.379  
Table 1b. Genotype and allele frequency distribution of CASP3 rs1049253 within 
male cases (ATP/INS/NON) and male controls (CON).  
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Figure 1. Schematic image of Chromosome 4 showing the location, size and exonic 
structure of the CASP3 gene, along with the location of CASP3 rs1049253 C/T in the 
3’-UTR of the gene (Chr.4:185548951). 
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